MyFinsight
Home
Blog
About
Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. (ELOX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the june 2026 publ...
Prepaid expenses and other curre...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable
Accrued expenses
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-4,502
-3,754
Stock-based compensation
95
46
Amortization of debt discount
8
7
Gain on extinguishment of accrued interest
0
56
Imputed interest expense on 2025 bridge loans
0
0
Change in fair value of warrant liabilities
62
-
License fee receivable
0
0
Unbilled receivable
0
0
Prepaid expenses and other current assets
-712
1,655
Accounts payable
-782
315
Accrued expenses
-382
-377
Accrued interest
0
-21
Net cash (used in) provided by operating activities
-4,789
-5,453
Proceeds from the june 2026 public offering, net of issuance costs
60,295
-
Proceeds from issuance of pre-funded warrants under the coastlands and domicilium securities purchase agreements, net of issuance costs
0
6,991
Repayment of term loan principal
0
0
Proceeds from debt financing obligations
0
0
Exercise of pre-funded warrants
91
-
Exercise of stock options
0
40
Net cash provided by (used in) financing activities
60,386
7,031
Increase in cash, cash equivalents and restricted cash
55,597
1,578
Cash, cash equivalents and restricted cash at the beginning of the period
6,369
4,791
Cash, cash equivalents and restricted cash at the end of the period
61,966
-
Cash and cash equivalents
61,960
-
Restricted cash
6
-
Total cash, cash equivalents and restricted cash
61,966
6,369
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the june
2026 public...
$60,295K
Exercise of pre-funded
warrants
$91K
Net cash provided by
(used in) financing...
$60,386K
Increase in cash, cash
equivalents and restricted...
$55,597K
Canceled cashflow
$4,789K
Prepaid expenses and
other current assets
-$712K
Stock-based compensation
$95K
Change in fair value of
warrant liabilities
$62K
Amortization of debt discount
$8K
Net cash (used in)
provided by operating...
-$4,789K
Canceled cashflow
$877K
Net loss
-$4,502K
Accounts payable
-$782K
Accrued expenses
-$382K
Buy us a coffee